Literature DB >> 31518176

Association Between Power Morcellation and Mortality in Women With Unexpected Uterine Cancer Undergoing Hysterectomy or Myomectomy.

Xiao Xu1, Haiqun Lin1, Jason D Wright2, Cary P Gross1, Francis P Boscoe3,4, Lindsey M Hutchison3, Peter E Schwartz1, Vrunda B Desai1,5.   

Abstract

PURPOSE: Despite concerns that power morcellation may adversely affect prognosis of patients with occult uterine cancer, empirical evidence has been limited and inconclusive. In this study, we aimed to determine whether uncontained power morcellation at the time of hysterectomy or myomectomy is associated with increased mortality risk in women with occult uterine cancer.
METHODS: By linking statewide hospital discharge records with cancer registry data in New York, we identified 843 women with occult endometrial carcinoma and 334 women with occult uterine sarcoma who underwent a hysterectomy or myomectomy for presumed benign indications during the period October 1, 2003, through December 31, 2013. Within this cohort, we compared disease-specific and all-cause mortality of women who underwent laparoscopic supracervical hysterectomy/laparoscopic myomectomy (LSH/LM), a surrogate indicator for uncontained power morcellation, with women who underwent supracervical abdominal hysterectomy and total abdominal hysterectomy (TAH), which did not involve power morcellation. Multivariable Cox regressions and propensity score method were used to adjust for patient characteristics.
RESULTS: Among women with occult uterine sarcoma, LSH/LM was associated with a higher risk for disease-specific mortality than TAH (adjusted hazard ratio [aHR], 2.66, 95% CI, 1.11 to 6.37; adjusted difference in 5-year disease-specific survival, -19.4%, 95% CI, -35.8% to -3.1%). In the subset of women with leiomyosarcoma, LSH/LM was associated with an increased risk for disease-specific mortality compared with supracervical abdominal hysterectomy (aHR, 3.64, 95% CI, 1.50 to 8.86; adjusted difference in 5-year disease-specific survival, -31.2%, 95% CI, -50.0% to -12.3%) and TAH (aHR, 4.66, 95% CI, 1.97 to 11.00; adjusted difference in 5-year disease-specific survival, -37.3%, 95% CI, -54.2% to -20.3%). Among women with occult endometrial carcinoma, there was no significant association between surgical approach and disease-specific mortality.
CONCLUSION: Uncontained power morcellation was associated with higher mortality risk in women with occult uterine sarcoma, especially in those with occult leiomyosarcoma.

Entities:  

Mesh:

Year:  2019        PMID: 31518176      PMCID: PMC6901279          DOI: 10.1200/JCO.19.00562

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  28 in total

1.  Operative laparoscopy: a second look after 18 years.

Authors:  Roy M Pitkin; William H Parker
Journal:  Obstet Gynecol       Date:  2010-05       Impact factor: 7.661

2.  The value of re-exploration in patients with inadvertently morcellated uterine sarcoma.

Authors:  Titilope Oduyebo; Alejandro J Rauh-Hain; Emily E Meserve; Michael A Seidman; Emily Hinchcliff; Suzanne George; Bradley Quade; Marisa R Nucci; Marcela G Del Carmen; Michael G Muto
Journal:  Gynecol Oncol       Date:  2013-12-01       Impact factor: 5.482

Review 3.  AAGL practice report: Morcellation during uterine tissue extraction.

Authors: 
Journal:  J Minim Invasive Gynecol       Date:  2014-05-24       Impact factor: 4.137

4.  Morcellation during Uterine Tissue Extraction: An Update.

Authors: 
Journal:  J Minim Invasive Gynecol       Date:  2018-03-23       Impact factor: 4.137

5.  Effects of morcellation of uterine smooth muscle tumor of uncertain malignant potential and endometrial stromal sarcoma: case series and recommendations for clinical practice.

Authors:  Erika L Mowers; Bethany Skinner; Karen McLean; R Kevin Reynolds
Journal:  J Minim Invasive Gynecol       Date:  2015-01-14       Impact factor: 4.137

6.  Hysterectomy surgery trends: a more accurate depiction of the last decade?

Authors:  Lindsay C Turner; Jonathan P Shepherd; Li Wang; Clareann H Bunker; Jerry L Lowder
Journal:  Am J Obstet Gynecol       Date:  2013-01-17       Impact factor: 8.661

Review 7.  Laparoscopic myomectomy and morcellation: A review of techniques, outcomes, and practice guidelines.

Authors:  Laura M Glaser; Jaclyn Friedman; Susan Tsai; Angela Chaudhari; Magdy Milad
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2017-09-29       Impact factor: 5.237

8.  Economic and Survival Implications of Use of Electric Power Morcellation for Hysterectomy for Presumed Benign Gynecologic Disease.

Authors:  Jason D Wright; Rosa R Cui; Anqi Wang; Ling Chen; Ana I Tergas; William M Burke; Cande V Ananth; June Y Hou; Alfred I Neugut; Sarah M Temkin; Y Claire Wang; Dawn L Hershman
Journal:  J Natl Cancer Inst       Date:  2015-10-08       Impact factor: 13.506

Review 9.  Options on fibroid morcellation: a literature review.

Authors:  Hans Brölmann; Vasilios Tanos; Grigoris Grimbizis; Thomas Ind; Kevin Philips; Thierry van den Bosch; Samir Sawalhe; Lukas van den Haak; Frank-Willem Jansen; Johanna Pijnenborg; Florin-Andrei Taran; Sara Brucker; Arnaud Wattiez; Rudi Campo; Peter O'Donovan; Rudy Leon de Wilde
Journal:  Gynecol Surg       Date:  2015-02-07

10.  Outcomes of uterine sarcoma found incidentally after uterus-preserving surgery for presumed benign disease.

Authors:  Jung-Yun Lee; Hyun Soo Kim; Eun Ji Nam; Sang Wun Kim; Sunghoon Kim; Young Tae Kim
Journal:  BMC Cancer       Date:  2016-08-23       Impact factor: 4.430

View more
  8 in total

1.  A novel morphology-based risk stratification model for stage I uterine leiomyosarcoma: an analysis of 203 cases.

Authors:  David B Chapel; Aarti Sharma; Ricardo R Lastra; Livia Maccio; Emma Bragantini; Gian Franco Zannoni; Suzanne George; Bradley J Quade; Carlos Parra-Herran; Marisa R Nucci
Journal:  Mod Pathol       Date:  2022-02-04       Impact factor: 7.842

Review 2.  Ultrasound-Guided Trans-Uterine Cavity Core Needle Biopsy of Uterine Myometrial Tumors to Differentiate Sarcoma from a Benign Lesion-Description of the Method and Review of the Literature.

Authors:  Maciej Stukan; Piotr Rutkowski; Jeremy Smadja; Sylvie Bonvalot
Journal:  Diagnostics (Basel)       Date:  2022-05-29

3.  Preclinical safety testing and initial experience of a morcellation bag with four sealable ports.

Authors:  Michael Anapolski; Anja Schellenberger; Ibrahim Alkatout; Dimitrios Panayotopoulos; Alexander Gut; Stefan Soltesz; Sven Schiermeier; Thomas Papathemelis; Günter K Noé
Journal:  Sci Rep       Date:  2021-10-22       Impact factor: 4.379

4.  Management of stage I occult uterine leiomyosarcoma: effects of morcellation, second-look surgery, and adjuvant treatments on survival.

Authors:  Jie Yang; Jiaxin Yang; Dongyan Cao; Lingya Pan; Ming Wu; Yang Xiang
Journal:  Ann Transl Med       Date:  2022-01

5.  A Novel Multi-Port Containment System for Laparoscopic Power Morcellation to Prevent Tumoral Spread: A Retrospective Cohort Study.

Authors:  Wenhui Wang; Haiyan Liang; Fang Zhao; Huan Yu; Chunhong Rong; Weiwei Feng; Qingyun Chen; Yanjun Yang; Qian Li; Dingqing Feng; Yuxiao Dong; Ming Xue; Jing Liang; Bin Ling
Journal:  Front Surg       Date:  2022-02-03

6.  Safety Warning about Laparoscopic Power Morcellation in Hysterectomy: A Cost-Effectiveness Analysis of National Impact.

Authors:  Xiao Xu; Vrunda B Desai; Peter E Schwartz; Cary P Gross; Haiqun Lin; Maria J Schymura; Jason D Wright
Journal:  Womens Health Rep (New Rochelle)       Date:  2022-03-28

7.  Endometrial Sampling for Preoperative Diagnosis of Uterine Leiomyosarcoma.

Authors:  Rosanne M Kho; Vrunda B Desai; Peter E Schwartz; Jason D Wright; Cary P Gross; Lindsey M Hutchison; Francis P Boscoe; Haiqun Lin; Xiao Xu
Journal:  J Minim Invasive Gynecol       Date:  2021-07-13       Impact factor: 4.137

8.  Differentiation of uterine low-grade endometrial stromal sarcoma from rare leiomyoma variants by magnetic resonance imaging.

Authors:  Yuki Himoto; Aki Kido; Akihiko Sakata; Yusaku Moribata; Yasuhisa Kurata; Ayako Suzuki; Noriomi Matsumura; Fuki Shitano; Seiya Kawahara; Shigeto Kubo; Shigeaki Umeoka; Sachiko Minamiguchi; Masaki Mandai
Journal:  Sci Rep       Date:  2021-09-27       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.